Rick Doblin
Founder and President of MAPS
Data updated
Research Footprint
Rick Doblin appears in 28 tracked papers (1991–2024), most studied alongside MDMA, Placebo and Psilocybin, across PTSD, Safety & Risk Management and Anxiety Disorders.
Most-cited paper: MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study (942 citations).
Frequent co-authors: Berra Yazar-Klosinski, Michael Mithoefer and Amy Emerson.
Publication Landscape
How the 28 papers Blossom tracks for Rick Doblin line up by year, topic, and journal. These are the psychedelic-relevant papers in Blossom's records as of July 2026, not a complete bibliography.
How has Rick Doblin's publishing grown?
SourcedTracked papers by publication year; 3 earlier papers published before 2010. Click a year for the running total.
Don't read as total output: only the 28 of 28 tracked papers with a recorded publication date are counted, and these are the psychedelic-relevant papers Blossom tracks, not a complete bibliography. The current year is still filling in.
What does Rick Doblin publish on?
SourcedTracked papers per topic. Orange marks the largest research focus.
Don't read shares as adding to 100%: a paper tagged with several topics counts once per topic. These are the psychedelic-relevant papers Blossom tracks, not a complete bibliography.
Where does Rick Doblin publish?
SourcedTracked papers per journal. Orange marks the most-used journal.
Counts the journal recorded on each tracked paper; preprints and papers with no journal on file are not shown. These are the psychedelic-relevant papers Blossom tracks, not a complete bibliography.
Background & Research
Rick Doblin is the founder of the Multidisciplinary Association for Psychedelic Studies (MAPS). For over three decades, he has led efforts to establish psychedelics as prescription medicines, focusing on the FDA approval of MDMA for PTSD. His work bridges public policy, clinical science, and advocacy, aiming to create a legal and safe context for the beneficial use of psychedelics for healing and growth.
Key Impact
The central figure in the global advocacy and regulatory maturation of MDMA-assisted therapy.
Collaboration Network
39 collaborators· click a node to visit their profile
Full network →Collaboration Network
See Rick Doblin's full collaboration network, shared papers, and research connections.
Compounds
Topics
Top Collaborators
Top Collaborators
Unlock clinical summaries, full texts, and related trial mapping.
Affiliations
Institutions, companies, and organisations Rick Doblin is associated with.